White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Show more
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen N.V (QIA) currently trades at €40.41, while our model-based Fair Value estimate is €34.59, 14.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €36.79 per share, and 2 of the 26 models we run sit above the €40.41 price.
Bear case: the Dividend Discount group reads lowest at €3.50, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €22.29 (bear) to €44.12 (bull), the price of €40.41 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Qiagen N.V reported revenue of $2.1B in FY2025 versus $2.3B in FY2021, a compound −1.8%/yr. Reported net income was $425M in FY2025, compounding −4.6%/yr from FY2021.
Key figures
Market cap €8.4B · P/E ratio 23.5 · P/S ratio 4.78 · EPS (TTM) €1.72 · Net margin 20.3% · Return on equity 11.9% · Return on assets (EBIT) 7.1% · Operating margin 23.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −14%, QIA screens richer than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€1.30 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€19.53
€32.77
€52.75
79
Growth DCF
€19.73
€31.16
€47.20
78
Residual Income
€14.62
€16.52
€22.30
76
All 26 models by family
DCF Models
FCF DCF
€19.53
€32.77
€52.75
79
Owner Earnings
€17.83
€30.09
€48.58
75
5Y Revenue Exit
€16.36
€28.10
€43.16
71
5Y EBITDA Exit
€23.31
€41.38
€62.78
74
5Y P/E Exit
€22.10
€39.07
€57.19
70
10Y Revenue Exit
€16.74
€27.70
€42.64
66
10Y EBITDA Exit
€21.67
€36.81
€57.58
67
10Y P/E Exit
€20.91
€35.22
€53.32
63
Earnings-Based
Graham-Dodd
€12.44
€42.91
€57.62
64
Lynch FV
€9.92
€14.16
€18.41
61
PEG = 1.0
€9.92
€14.16
€18.41
57
EPV
€14.30
€17.11
€19.54
74
Dividend Discount
Gordon GGM
€2.05
€4.09
€6.19
67
DDM Multi-Stage
€2.05
€3.50
€4.32
67
Multiples
P/E Multiple
€30.20
€40.26
€50.33
63
P/S Multiple
€23.33
€31.11
€38.89
58
P/B Multiple
€23.33
€31.11
€38.89
55
EV/EBIT
€25.06
€34.59
€44.11
66
EV/EBITDA
€28.78
€39.55
€50.31
67
EV/Revenue
€15.39
€23.49
€31.60
53
Asset-Based
NCAV (Graham)
€8.14
€10.90
€16.27
54
Growth DCF
Growth DCF
€19.73
€31.16
€47.20
78
Rev-Margin DCF
€16.36
€28.13
€42.07
72
Economic Profit
Residual Income
€14.62
€16.52
€22.30
76
ROIC Compounder
€14.30
€17.69
€23.16
72
Growth Earnings
Growth-Adj P/E
€25.76
€36.79
€47.83
67
Open the full fair value analysis →
Overall quality
71/100
Of which business quality 70
· Market factors (momentum, volatility) 59
Profitability
47
Margins and returns on capital today
Quality Growth
43
Are margins and returns improving?
Cashflow
79
Earnings quality: real cash, not paper profit
Fin. Strength
78
Balance sheet, leverage, solvency risk
Investment
81
Disciplined investing over empire-building
Low Volatility
75
Calm price path (market factor)
Momentum
52
Price trend over the last 3–12 months (market factor)
52W Momentum
53
Distance to the 52-week high (market factor)
Net Issuance
99
Share count: buybacks or dilution?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Qiagen N.V (QIA) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of €34.59 versus a price of €40.41, about −14% upside (overvalued).
What is the fair value of QIA?
Our model-based fair value for Qiagen N.V is €34.59 (as of Oct 3, 2026), built from audited fundamentals. The current price: €40.41.
What is the quality score of QIA?
Qiagen N.V has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qiagen N.V (QIA)?
Our model-based price target is the fair value of €34.59 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario €22.29, optimistic scenario €44.12. It is a calculation from audited fundamentals, not an analyst target.
What is the Qiagen N.V stock forecast for 2026?
Our models put fair value at €34.59, about −14% upside versus a price of €40.41 (overvalued). Cautious scenario €22.29, optimistic scenario €44.12. The calculation is refreshed regularly with new filings.
What is the revenue of Qiagen N.V (QIA)?
Qiagen N.V reported trailing-twelve-month revenue of about $2.1B (latest available figure, as of Oct 3, 2026).
What growth is priced into Qiagen N.V (QIA)?
For today's price to be fair in a discounted-cash-flow model, Qiagen N.V would have to grow free cash flow by +8.6 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.3 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of QIA use?
Our models discount Qiagen N.V at 8.7 %: a base by market capitalisation (mid), damped by beta 0.64, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Qiagen N.V that is +8.6 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Qiagen N.V (QIA) delivered so far?
Over the past 5 years revenue at Qiagen N.V grew +2.3 % a year. The price currently implies +8.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Qiagen N.V (QIA) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Qiagen N.V (+8.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Qiagen N.V (QIA)?
The free-cash-flow yield on the price is 4.79 %: that much free cash flow Qiagen N.V produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Qiagen N.V (QIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qiagen N.V it is €34.59 per share (as of Oct 3, 2026), against a price of €40.41. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Qiagen N.V stock overvalued or undervalued in 2026?
As of Oct 3, 2026, QIA trades above its calculated fair value: price €40.41, fair value €34.59, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QIA?
No. The price is what the market pays today (€40.41); the fair value is what the company's own numbers justify (€34.59). For Qiagen N.V the two are €5.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Qiagen N.V worth?
The market values Qiagen N.V at about €8.4B (market capitalisation, as of Oct 3, 2026). Per share that is €40.41; our models calculate a fair value of €34.59 per share.
What do the bullish and bearish scenarios say about QIA?
Our models span a range for Qiagen N.V: cautious scenario €22.29, base €34.59, optimistic €44.12 per share (as of Oct 3, 2026, price €40.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is QIA from its 52-week high?
Qiagen N.V trades at €40.41, about 12% below its 52-week high of €46.01 and 45% above the low of €27.86 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €34.59 is for.
Which stocks are comparable to Qiagen N.V?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qiagen N.V stock attractive at the current price?
The data as of Oct 3, 2026: price €40.41, calculated fair value €34.59 (−14%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QIA calculated?
We run Qiagen N.V through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €34.59, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Qiagen N.V itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Qiagen N.V (QIA)?
The closing price on Oct 2, 2026 was €40.41. Our model-based fair value is €34.59, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qiagen N.V right now?
A fairly wide model range (€22.29 to €44.12) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Qiagen N.V
How large is the market capitalisation of Qiagen N.V (QIA)?
The market capitalisation of Qiagen N.V is €8.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Qiagen N.V (QIA)?
The price-to-earnings ratio of Qiagen N.V is 23.5. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Qiagen N.V (QIA)?
The price-to-sales ratio of Qiagen N.V is 4.78 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qiagen N.V (QIA)?
Earnings per share at Qiagen N.V are €1.72 (price ÷ EPS = P/E 23.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Qiagen N.V (QIA)?
The net margin of Qiagen N.V is 20.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qiagen N.V (QIA)?
The return on equity (ROE) of Qiagen N.V is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qiagen N.V (QIA)?
On an EBIT basis the return on assets of Qiagen N.V is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qiagen N.V (QIA)?
The operating margin of Qiagen N.V is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qiagen N.V (QIA)?
Revenue at Qiagen N.V is growing +1.8% versus a year earlier (3y avg −0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qiagen N.V (QIA)?
Earnings per share at Qiagen N.V are growing −23.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Qiagen N.V (QIA) carry?
The net debt of Qiagen N.V is $815M (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
